These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6553606)

  • 21. [Clinical experience with BRL 25000 (clavulanic acid-amoxicillin) granules in pediatric infections].
    Nagata K; Yokoyama M
    Jpn J Antibiot; 1985 Feb; 38(2):263-8. PubMed ID: 4009948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects.
    Weber DJ; Tolkoff-Rubin NE; Rubin RH
    Pharmacotherapy; 1984; 4(3):122-36. PubMed ID: 6739312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of BRL 25000 (clavulanic acid-amoxicillin) on bacterial flora in human feces].
    Motohiro T; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Fujimoto T; Nishiyama T; Kuda N; Ishimoto K
    Jpn J Antibiot; 1985 Feb; 38(2):441-80. PubMed ID: 3847525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro susceptibilities of BRL 25000 (clavulanic acid-amoxicillin) against causative organisms in the field of obstetrics and gynecology].
    Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Yoshihara H; Oda S; Matsumoto Y; Ikegami R; Sato K
    Jpn J Antibiot; 1986 Mar; 39(3):842-52. PubMed ID: 3488425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amoxicillin-clavulanic acid (Augmentin).
    Med Lett Drugs Ther; 1984 Nov; 26(674):99-100. PubMed ID: 6387417
    [No Abstract]   [Full Text] [Related]  

  • 26. Distribution of amoxicillin and clavulanic acid in infected animals and efficacy against experimental infections.
    Boon RJ; Beale AS; Comber KR; Pierce CV; Sutherland R
    Antimicrob Agents Chemother; 1982 Sep; 22(3):369-75. PubMed ID: 7137980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmaceutical preparation of BRL 25000].
    Jpn J Antibiot; 1985 Feb; 38(2):538-41. PubMed ID: 3847526
    [No Abstract]   [Full Text] [Related]  

  • 28. Penicillin gets some help against resistant pathogens.
    Henehan J
    JAMA; 1982 Nov; 248(19):2427. PubMed ID: 6922944
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental and clinical studies of BRL 25000 (clavulanic acid-amoxicillin) granules in the field of pediatrics].
    Minamitani M; Hachimori K; Kaneda K
    Jpn J Antibiot; 1985 Feb; 38(2):415-22. PubMed ID: 4009950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amoxycillin/clavulanate in acute purulent exacerbations of chronic bronchitis.
    Maesen FP; Davies BI; Baur C
    J Antimicrob Chemother; 1987 Mar; 19(3):373-83. PubMed ID: 3494724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of augmentin against clinically important gram-positive and gram-negative bacteria in comparison with other antibiotics.
    Focht J; Klietmann W; Heilmann HD
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Apr; 256(4):523-30. PubMed ID: 6564828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro susceptibilities of causative organisms isolated from patients with primary respiratory tract infections to BRL 25000 (clavulanic acid/amoxicillin)].
    Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Oda S; Matsumoto Y; Ikegami R; Sato K; Fukumoto T
    Jpn J Antibiot; 1985 Oct; 38(10):2797-808. PubMed ID: 3878415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical study of amoxicillin used in the otorhinolaryngological field (author's transl)].
    Okamoto K; Yoshida A; Kona A; Ikeda M; Muraoka J
    Jpn J Antibiot; 1976 Jan; 29(1):22-6. PubMed ID: 1263338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients.
    Schaad UB; Casey PA; Cooper DL
    Antimicrob Agents Chemother; 1983 Feb; 23(2):252-5. PubMed ID: 6838187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmentin (Amoxycillin and clavulanic acid) in the treatment of urinary tract infections and skin and soft tissue infections.
    Tan TH; Tay L; Yeo M; Feng PH
    Singapore Med J; 1983 Oct; 24(5):299-302. PubMed ID: 6669995
    [No Abstract]   [Full Text] [Related]  

  • 36. [Preliminary evaluation of the sensitivity of selected bacteria to amoxicillin and augmentin in comparison with other antibiotics used to date].
    Ruczkowska J; Dolna I
    Przegl Lek; 1984; 41(4):321-4. PubMed ID: 6565294
    [No Abstract]   [Full Text] [Related]  

  • 37. Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis.
    Sydnor TA; Scheld WM; Gwaltney J; Nielsen RW; Huck W; Therasse DG
    Ear Nose Throat J; 1992 May; 71(5):225-32. PubMed ID: 1505371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of augmentin as a beta-lactam antibiotic in surgical and medical practice.
    Kirei BR; Mhalu FS; Pallangyo PK; Seif SA
    East Afr Med J; 1987 Jul; 64(7):499-503. PubMed ID: 3691365
    [No Abstract]   [Full Text] [Related]  

  • 39. Beta-lactamase inhibitors: another approach to overcoming antimicrobial resistance.
    Parker RH; Eggleston M
    Infect Control; 1987 Jan; 8(1):36-40. PubMed ID: 3028975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative activity of BRL 25.000 with amoxycillin against resistant clinical isolates.
    Van Landuyt HW; Pyckavet M; Lambert AM
    J Antimicrob Chemother; 1981 Jan; 7(1):65-70. PubMed ID: 6907270
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.